title: Preparation, characterization, and in vitro evaluation of bleomycin-containing nanoliposomes.
abstract: Bleomycin is an anticancer drug used against various types of cancers. The aim of this study was to prepare a new PEGylated and non-PEGylated nanoliposomal formulation of bleomycin (PEG-nLip-BLM and nLip-BLM) and evaluate their anticancer activity in different tumor cell lines. The liposomes were prepared by thin-film hydration method, and then, bleomycin (BLM) was loaded to the prepared vesicles. The size, zeta potential, entrapment efficiency, loading rate, release profile, and cytotoxicity of liposomal formulations in TC-1, LLC1, and HFLF-PI5 cell lines were investigated. Mean particle size and zeta potential of the PEG-nLip-BLM and nLip-BLM were found to be 99.4 ± 4.6 nm and -34.83 ± 4.7 mV; and 112.2 ± 7.2 nm and -27.5 ± 3.2 mV, respectively, which were stable for at least 2 months. Encapsulation and loading efficiency of BLM for PEG-nLip-BLM and nLip-BLM were obtained about 83.1 ± 4.2% and 14.3 ± 2.5%; and 78.3 ± 8.6% and 11.1 ± 3.3%, respectively. Drug release study showed a slow release pattern without considerable burst effect. The liposomal formulations indicated lower toxicity compared to free drug in case of TC-1 and HFLF-PI5 cells, but their cytotoxicity against LLC1 cells was significantly higher than free drug. The results of this study indicated that PEG-nLip-BLM can be a suitable candidate for drug delivery to solid tumors.
authors.affiliation: Pilot Nanobiotechnology Department, Pasteur Institute of Iran, Tehran, Iran.
authors.forename: Mohsen
authors.initials: M
authors.lastname: Chiani
authors.affiliation: National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran.
authors.forename: Mohammad Ali
authors.initials: MA
authors.lastname: Shokrgozar
authors.affiliation: Virology Department, Pasteur Institute of Iran, Tehran, Iran.
authors.forename: Kayhan
authors.initials: K
authors.lastname: Azadmanesh
authors.affiliation: Pilot Nanobiotechnology Department, Pasteur Institute of Iran, Tehran, Iran.
authors.forename: Dariush
authors.initials: D
authors.lastname: Norouzian
authors.affiliation: Pilot Nanobiotechnology Department, Pasteur Institute of Iran, Tehran, Iran.
authors.forename: Mohammad Reza
authors.initials: MR
authors.lastname: Mehrabi
authors.affiliation: Clinical Biochemistry Department, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.
authors.forename: Aazam
authors.initials: A
authors.lastname: Najmafshar
authors.affiliation: Pilot Nanobiotechnology Department, Pasteur Institute of Iran, Tehran, Iran.
authors.forename: Azim
authors.initials: A
authors.lastname: Akbarzadeh
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D001761:Bleomycin / Q000494:pharmacology*; D002460:Cell Line; D045744:Cell Line, Tumor; D006801:Humans; D008081:Liposomes; D051379:Mice; D008855:Microscopy, Electron, Scanning; D049329:Nanostructures
chemical_list: D000903:Antibiotics, Antineoplastic; D008081:Liposomes; D001761:Bleomycin
keywords: bleomycin; cytotoxicity; drug delivery; nanoliposomes